QuidelOrtho (QDEL) to Release Quarterly Earnings on Thursday

QuidelOrtho (NASDAQ:QDEL) will be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.30 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

QuidelOrtho Price Performance

QDEL stock opened at $39.09 on Tuesday. The company has a current ratio of 1.44, a quick ratio of 0.79 and a debt-to-equity ratio of 0.70. QuidelOrtho has a 1 year low of $29.74 and a 1 year high of $75.86. The stock’s fifty day moving average is $42.51 and its two-hundred day moving average is $40.44.

Wall Street Analyst Weigh In

QDEL has been the topic of a number of recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 target price on shares of QuidelOrtho in a research note on Friday, August 16th. Craig Hallum upgraded QuidelOrtho from a “hold” rating to a “buy” rating and raised their target price for the company from $40.00 to $57.00 in a research note on Thursday, September 5th. Finally, UBS Group started coverage on shares of QuidelOrtho in a research note on Thursday, September 19th. They set a “neutral” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $58.83.

Insider Activity at QuidelOrtho

In other QuidelOrtho news, major shareholder Carlyle Group Inc. sold 78,180 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.94, for a total value of $3,122,509.20. Following the sale, the insider now directly owns 8,441,022 shares in the company, valued at approximately $337,134,418.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.